Brain Ischemia pp 105-119 | Cite as

Fibrinolysis and its Relevance to Acute Focal Cerebral Ischemia

  • G. J. del Zoppo


The use of thrombolytic agents in the treatment of acute cerebral ischemia is experimental. Approximately 80%–90% of focal cerebral ischemic events presenting as strokes within 8–24 hours of symptom onset (Solis et al. 1977) and 50%–70% of all strokes prospectively entered in contemporary stroke registries (Mohr et al. 1978; Kunitz et al. 1984) are due to atherothrombotic and embolic occlusive disease. It is on this basis that efforts to evaluate the efficacy of thrombus lysis in acute stroke have attracted renewed interest.


Plasminogen Activator Acute Stroke Acute Ischemic Stroke Thrombolytic Therapy Tissue Plasminogen Activator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe T, Kazama M, Naito I et al. (1981a) Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-bind study. Blood Vessels 12: 321 - 341Google Scholar
  2. Abe T, Kazawa M, Naito I (1981b) Clinical effect of urokinase (60 000 units/day) on cerebral infarction: comparative study by means of multiple-center double-blind test. Blood Vessels 12: 342–358Google Scholar
  3. Abe T, Terashi A, Tohgi H, Sasoh S, Naito I (1990) Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombosis. Clin Eval 18: 39–69Google Scholar
  4. Adilgaard U (1969) Binding of thrombin to antithrombin III. Scand J Clin Lab Invest 24: 23–27Google Scholar
  5. Aldrich MS, Sherman SA, Greenberg HS (1985) Cerebrovascular complications of streptokinase infusion. JAMA 253: 1777–1779PubMedGoogle Scholar
  6. Araki G, Minakami K, Mihara H (1973) Therapeutic effect of urokinase on cerebral infarction. Rinsho to Kenkyu 50: 3317–3326Google Scholar
  7. Astrup J, Symon L, Branston NM, Lassen N (1977) Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 8: 51–57PubMedGoogle Scholar
  8. Atarashi J, Otomo E, Araki G, Itoh E, Togi H, Matsuda T (1985) Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis. Multicenter double-blind study in comparison with placebo. Clin Eval 13:659–709Google Scholar
  9. Atarashi J, Otomo E, Araki G, Itoh E, Togi H, Matsuda T (1985) Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis. Multicenter double-blind study in comparison with placebo. Clin Eval 13: 659–709Google Scholar
  10. Atkin N, Nitzberg S, Dorsey J (1964) Lysis of intracerebral thromboembolism with fibrinolysis Report of a case. Angiology 15: 346–439Google Scholar
  11. Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB (1989) Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 29: 1500–1503Google Scholar
  12. Bach RR (1988) Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 23: 339–368PubMedGoogle Scholar
  13. Bando H, Okada K, Matsuo O (1987) Thrombolytic effect of prourokinase in vitro. J Fibrinol 1: 169–176Google Scholar
  14. Bauer PI, Machovich R, Aranyi P, Buki KG, Csonke E, Horvath I (1983) Mechanism of thrombin binding to endothelial cells. Blood 61: 368–372PubMedGoogle Scholar
  15. Berliner S, Niiya K, Roberts JR, Houghten RA, Ruggeri ZM (1988) Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein Ilb-IIIa without interacting with other adhesive molecules. J Biol Chem 263: 7500–7505PubMedGoogle Scholar
  16. Bernick MB, Kwaan HC (1969) Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest 48: 1740–1753Google Scholar
  17. Bloom AL, Thomas DP (eds) (1987) Haemostasis and thrombosis. Churchill Livingstone, EdinburghGoogle Scholar
  18. Brogden RN, Speight TM, Avery GS (1973) Streptokinase: a review of its clinical pharmacology, mechanism of action, and therapeutic uses. Drugs 5: 357–445PubMedGoogle Scholar
  19. Brott T, Haley C, Levy D et al. (1990) Safety and potential efficacy of tissue plasminogen activator (t-PA) for stroke. Stroke 21: 181Google Scholar
  20. Brott TG, Haley EC, Levy DE et al. (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plaminogen activator administered within 90 minutes. Stroke 23: 632–640PubMedGoogle Scholar
  21. Bruckmann H, Ferbert A (1989) Putaeminal hemorrhage after recanalization of an embolic MCA occlusion treated with tissue plasminogen activator. Neuroradiology 31: 95–97PubMedGoogle Scholar
  22. Buteux G, Jubault V, Suisse A (1988) Local recombinant tissue plasminogen activator to clear cerebral artery thrombosis developing soon after surgery Lancet 1: 1143–1144Google Scholar
  23. Castellino FJ (1979) A unique enzyme-protein substrate modifier reaction: plasmin/streptokinase interaction. Trends Biochem Sci 4: 1–5Google Scholar
  24. Clarke RL, Cliffton EE (1960) The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol 30: 546–551Google Scholar
  25. Collen D, Lijnen HR (1986) The fibrinolytic system in men. CRC Crit Rev Oncol Hematol 4: 249Google Scholar
  26. Collen D, Lijnen HR, Stassen JM (1992) Thrombolytic properties of staphylokinase and streptokinase in experimental animal models. Fibrinolysis 6 (Suppl 2): 29 (Abstract)Google Scholar
  27. Colucci M, Balconi G, Lorenzet R et al. (1983) Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71: 1893–1896PubMedGoogle Scholar
  28. Comp PC, Jacocks RM, Ferrell GL, Esmon CT (1982) Activation of protein C in vivo. J Clin Invest 70: 127–134PubMedGoogle Scholar
  29. Curtis CG (1987) Plasma factor XIII. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, Edinburgh, p 217Google Scholar
  30. Dalai PM, Shah PM, Aiyar RR (1965a) Arteriographic study of cerebral embolism. Lancet 2: 358–361Google Scholar
  31. Dalai PM, Shah PM, Sheth SC, Deshparde CK (1965b) Cerebral embolism: angiographic observations on spontaneous clot lysis. Lancet 1: 61–64Google Scholar
  32. Damus PS, Hicks M, Rosenberg RD (1973) Anticoagulant action of heparin. Nature 246: 355–357PubMedGoogle Scholar
  33. del Zoppo GJ (1988) Thrombolysis: new concepts in the treatment of stroke. In: Hennerici M, Sitzer G, Weger H-D (eds) Carotid artery plaques. Karger, Basel, pp 247–272Google Scholar
  34. del Zoppo GJ (1990) Relevance of focal cerebral ischemia models. Experience with fibrinolytic agents. Stroke 21: IV155–IV160Google Scholar
  35. del Zoppo GJ, Mori E (1992) Hematologic causes of intracerebral hemorrhage and their treatment. In: Batjer HH (ed) Spontaneous intracerebral hemorrhage. Neurosurg Clin North Am 3 (3): 637–658Google Scholar
  36. del Zoppo GJ, Zeumer H, Harker LA (1986a) Thrombolytic therapy in acute stroke: possibilities and hazards. Stroke 17: 595–607PubMedGoogle Scholar
  37. del Zoppo GJ, Copeland BR, Waltz TZ, Tyroff J, Plow EF, Harker LA (1986b) The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 17: 638–643PubMedGoogle Scholar
  38. del Zoppo GJ, Ferbert A, Otis S et al. (1988) Local intraarterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke 19: 307–313PubMedGoogle Scholar
  39. del Zoppo GJ, Poeck K, Pessin MS et al. (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedGoogle Scholar
  40. del Zoppo GJ, Mori E, Hacke W (1993) Thrombolytic therapy in acute ischemic stroke I I. Springer-Verlag, HeidelbergGoogle Scholar
  41. Drake ME, Shin C (1983) Conversion of ischemic to hemorrhagic infarction by anticoagulant administration. Report of two cases with evidence from serial computed tomographic brain scans. Arch Neurol 40: 44–46Google Scholar
  42. Drake TA, Hannani K, Fei H, Lavi S, Berliner JA (1991) Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 138: 601–607PubMedGoogle Scholar
  43. Ehrlich HJ, Bang NW, Little SP et al. (1987) Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. Fibrinolysis 1: 75–81Google Scholar
  44. Fieschi C, Bozzao L (1969) Transient embolic occlusion of the middle cerebral and internal carotid arteries in cerebral apoplexy. J Neurol Neurosurg Psych 32: 236–240Google Scholar
  45. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L (1989) Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 91: 311–321PubMedGoogle Scholar
  46. Fisher CM, Adams RD (1951) Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 10: 92–94PubMedGoogle Scholar
  47. Fisher CM, Adams RD (1987) Observations on brain embolism with special reference to hemorrhage infarction. In; Furlan AJ (ed) The heart and stroke. Exploring mutual cerebrovascular and cardiovascular issues. Springer-Verlag, New York, pp 17–36Google Scholar
  48. Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F (1965) The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 65: 713–731Google Scholar
  49. Fletcher AP, Alkjaersig N, Lewis M et al. (1976) A pilot study of urokinase therapy in cerebral infarction. Stroke 7: 135–142PubMedGoogle Scholar
  50. Furlan AJ, Cavalier SJ, Hobbs RE, Weinstein MA, Modic MI (1982) Hemorrhage and anticoagulation after nonseptic embolic brain infarction. Neurology 32: 280–282PubMedGoogle Scholar
  51. Gaffney PJ (1987) Fibrinolysis. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, London, pp 223–244Google Scholar
  52. Gaffney PJ, Whittaker AN (1979) Fibrin cross-links and lysis rates. Thromb Res 14: 85–94PubMedGoogle Scholar
  53. Gandell SJ (1992) Vampire bat salivary plasminogen activator (Bat-PA): exploration of efficacy and safety using animal models of arterial thrombosis and bleeding. Fibrinolysis 6 (Suppl 2): 28 (Abstract)Google Scholar
  54. Gheysen D, Lijnen HR, Pierard L et al. (1987) Characterization of a recombinant fusion protein of the kringle domain of tissue-type plasminogen activator with a truncated single chain urokinase type plasminogen activator. J Biol Chem 262: 11779–11784PubMedGoogle Scholar
  55. Groskopf WR, Summaria L, Robbins KC (1969) Studies on the active center of human plasmin. Partial amino acid sequence of a peptide containing the active center serine residue. J Biol Chem 224: 3590Google Scholar
  56. Gunzler WA, Steffens GJ, Otting F, Buse G, Flohe L (1982) Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 563: 133–141Google Scholar
  57. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ (1988) Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar oclusive disease. Stroke 19: 1216–1222PubMedGoogle Scholar
  58. Haley EC, Levy DE, Brott TG et al. (1992) Urgent therapy for stroke. Part II. Pilot study of plasminogen administered 91-180 minutes from onset. Stroke 23: 641–645PubMedGoogle Scholar
  59. Hanaway J, Torack R, Fletcher AP, Landau WM (1976) Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 7: 143–146PubMedGoogle Scholar
  60. Hart RG (1986) Cerebral Embolism Study Group: timing of hemorrhagic transformation of cardioembolic stroke. In: Stober T (ed) Central nervous system control of the heart. Martinus Nijhoff Publishing, Boston, pp 229–232Google Scholar
  61. Henze TH, Boeer A, Tebbe U, Romatowski J (1987) Lysis of basilar artery occlusion with tissue plasminogen activator. Lancet 1: 1391Google Scholar
  62. Herderschee D, Limburg U, Hijdra A, Koster PA (1991) Recombinant tissue plasminogen activator in two patients with basilar artery occlusion. J Neurol Neurosurg Psych 54: 71–73Google Scholar
  63. Herndon RM, Meyer JS, Johnson JF, Landers J (1960) Treatment of cerebrovascular thrombosis with fibrinolysin. Preliminary report. Am J Cardiol 30: 540–545Google Scholar
  64. Hornig CR, Dorndorf W, Agnoli AL (1986) Hemorrhagic cerebral infarction: a prospective study. Stroke 17: 179–185PubMedGoogle Scholar
  65. Irino T, Taneda M, Minami T (1977) Angiographic manifestations in post-recanalized cerebral infarction. Neurology 27: 471–475PubMedGoogle Scholar
  66. Ito Z, Suzuki A, Hen R, Menura K (1983) Prognostic factors in spontaneous recanalization of middle cerebral artery occlusion. In: Ito Z, Kutsuzawa T, Yasui N (eds) Cerebral ischemia-an update. Exerpta Medica, Amsterdam, pp 159–166Google Scholar
  67. Jacobson CD, Chandler AB (1965) Thrombolysis in vivo. I. Method, comparison of various thrombolytic agents and factors influencing thrombolysis. Scand J Clin Lab Invest 17 (Suppl 84): 209–224Google Scholar
  68. Koller RL (1982) Recurrent embolic cerebral infarction and anticoagulation. Neurology 32: 283–285PubMedGoogle Scholar
  69. Koudstaal PJ, Stibbe J, Vermeulen M (1988) Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br Med J 297: 1571–1574Google Scholar
  70. Kruithoff EKO (1988) Inhibitors of plasminogen activators. In: Kluft C (ed) Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Volume 1. CRC Press, Boca Raton, pp 190–210Google Scholar
  71. Kruithof EKO, Tran-Thang C, Bachmann F (1986) The fastacting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost 55: 65–69PubMedGoogle Scholar
  72. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann R (1984) Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 68: 907Google Scholar
  73. Kunitz SC, Gross CR, Heyman A et al. (1984) The pilot stroke data bank: definition, design and data. Stroke 15: 740–746PubMedGoogle Scholar
  74. Levin EG, Loskutoff DJ (1982) Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 94: 631PubMedGoogle Scholar
  75. Levin EG, Santell L (1987) Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 105: 2543–2549PubMedGoogle Scholar
  76. Levin EG, Santell L (1988) Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells. J Biol Chem 263: 6502–6507Google Scholar
  77. Levin EG, Stern DM, Nawroth PP et al. (1986) Specificity of the thrombin-induced release of tissue plasminogen activator from cultured human endothelial cells. Thromb Haemost 56: 115–119PubMedGoogle Scholar
  78. Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D (1986) Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 261: 1253–1258Google Scholar
  79. Lodder J, Krijne-Kubat B, van der Lugt PJM (1988) Timing of autopsy-confirmed hemorrhagic infarction with reference to cardioembolic stroke. Stroke 19: 1482–1484PubMedGoogle Scholar
  80. Lollar P, Owen WG (1980) Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. J Clin Invest 66: 1222–1230PubMedGoogle Scholar
  81. Majerus PW, Miletich JP, Kane WP, Hoffmann SL, Stanford N, Jackson CM (1980) The formation of thrombin on platelet surface. In: Mann KG, Taylor FB (eds) The regulation of coagulation. Elsevier/North Holland, New York, p 215Google Scholar
  82. Matsumoto K, Satoh K (1991) Topical intraarterial urokinase infusion for acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer-Verlag, Heidelberg, pp 207–212Google Scholar
  83. Matsuo O, Collen D, Verstraete M (1981) On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). Thromb Res 347: 358Google Scholar
  84. Meyer JS, Herndon RM, Gotoh F, Tazaki Y, Nelson JN, Johnson JF (1961) Therapeutic thrombolysis. In: Millikan CH, Siekert RG, Whisnant JP (eds) Cerebral vascular dis- Brain Ischemia: Basic Concepts and Clinical Relevance ease. Third Princeton Conference, Grune and Stratton, New York, pp 160–177Google Scholar
  85. Meyer JS, Gilroy J, Barnhart MI, Johnson JF (1963) Therapeutic thrombolysis in cerebral thromboembolism. Neurology 13: 927–937PubMedGoogle Scholar
  86. Meyer JS, Gilroy J, Barnhart MI, Johnson JF (1964) Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 189: 373PubMedGoogle Scholar
  87. Miyakawa T (1984) The cerebral vessels and thrombosis. Rinsho Ketsueki 25: 1018–1026PubMedGoogle Scholar
  88. Mobius E, Berg-Dammer E, Kiihne D, Ahser HC (1991) Local thrombolytic therapy in acute basilar artery occlusion: experience with 18 patients. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer-Verlag, Heidelberg, pp 213–215Google Scholar
  89. Mohr JP, Caplan LR, Melski JW et al. (1978) The Harvard Cooperative Stroke Registry: a prospective registry of patients hospitalized with stroke. Neurology 28: 754–762PubMedGoogle Scholar
  90. Moncada S, Vane JR (1979) Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. New Engl J Med 300: 1142–1147PubMedGoogle Scholar
  91. Mori E (1991) Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer-Verlag, Heidelberg, pp 137–146Google Scholar
  92. Mori E, Tabuchi M, Yoshida T, Yamadori A (1988) Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 19: 802–812PubMedGoogle Scholar
  93. Mori E, Yoneda Y, Ohkawa S et al. (1991) Double-blind placebo-controlled trial of intravenous recombinant tissue plasminogen activator (rt-PA) in acute carotid stroke. Neurology 41 (Suppl 1): 347Google Scholar
  94. Mori E, Yoneda Y, Tabuchi M et al. (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982PubMedGoogle Scholar
  95. Morrissey JH, Revak D, Tejada P, Fair DS, Edgington TS (1988) Resolution of monomeric and heterodimeric forms of tissue factor, the high affinity cellular receptor for factor VII. Thromb Res 50: 481–493PubMedGoogle Scholar
  96. Mustard JF, Packham MA, Kinlough-Rathbone RL (1987) Mechanisms in thrombosis. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis, 2nd edn. Churchill Livingstone, Edinburgh, pp 618–650Google Scholar
  97. Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E (1983) Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 34: 561 - 571PubMedGoogle Scholar
  98. Niemetz J (1972) Coagulant activity of monocytes. J Clin Invest 51: 307–313PubMedGoogle Scholar
  99. Niemetz J, Morrison DC (1977) Lipid A as the biologically active moiety in bacterial endotoxin ( LPS)-initiated generation of procoagulant activity by peripheral blood leukocytes. Blood 49: 947–955Google Scholar
  100. Ogata J, Yutani C, Imakita M et al. (1989) Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 20: 876–883PubMedGoogle Scholar
  101. Okada Y, Yamaguchi T, Minematsu K et al. (1989) Hemorrhagic transformation in cerebral embolism. Stroke 20: 598–603PubMedGoogle Scholar
  102. Otomo E, Araki G, Itoh E, Tohgi H, Matsuda T, Atarashi J (1985) Clinical efficacy of urokinase in the treatment of cerebral thrombosis: multicenter double-blind study in comparison with placebo. Clin Eval 13: 711–751Google Scholar
  103. Otomo E, Tohgi H, Hirai S et al. (1988) Clinical efficacy of AK- 124 (tissue plasminogen activator) in the treatment of cerebral thrombosis: study by means of multicenter double blind comparison with urokinase. Yakuri To Chiryo 16: 3775–3821Google Scholar
  104. Ott BR, Zamani A, Kleefield J, Funkenstein HH (1986) The clinical spectrum of hemorrhagic infarction. Stroke 17: 630–637PubMedGoogle Scholar
  105. Owren P (1944) New investigations on the coagulation of blood. Proc Norwegian Acad Sci 21Google Scholar
  106. Pelz P, Ladumer G, Giebritz E (1991) Neuropathological findings after thrombolytic therapy in acute ischemic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M (eds)Thrombolytic therapy in acute ischemic stroke. Springer- Verlag, Heidelberg, pp 224–227Google Scholar
  107. Pessin MS, del Zoppo GJ, Estol CJ (1990) Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 13: 271–289PubMedGoogle Scholar
  108. Pessin MS, Teal PA, Caplan LR (1991) Hemorrhagic infarction: guilt by association. AJNR 12: 1123–1126PubMedGoogle Scholar
  109. Pierard L, Jacobs P, Gheysen D et al. (1987) Mutant and chimeric recombinant plasminogen activators. J Biol Chem 262: 11771–11778PubMedGoogle Scholar
  110. Ranby M, Bergsdorf N, Nilsson T (1982a) Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 27: 175–183PubMedGoogle Scholar
  111. Ranby M, Bergsdorf N, Norrman B, Svenson E, Wallen P (1982b) Tissue plasminogen activator kinetics. In: Davison JF, Bachmann F, Bouvier CA, Kruithof EKO (eds) Progress in fibrinolysis. Volume VI. Churchill-Livingstone, New York, p 182Google Scholar
  112. Rickli EE (1975) The activation mechanism of human plasminogen. Thromb Diathes Haem 34: 386–395Google Scholar
  113. Rijken DC (1988) Structure/function relationships of t-PA. In: Kluft C (ed) Tissue type plasminogen activator (t-PA): physiological and clinical aspects. Volume 1. CRC Press, Boca Raton, pp 101–122Google Scholar
  114. Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissuetype) plasminogen activator. J Biol Chem 257: 2920–2925PubMedGoogle Scholar
  115. Robbins KC, Summaria L, Hsieh B, Shah RJ (1967) The peptide chains of human plasmin. J Biochem 242: 2333–2342Google Scholar
  116. rt-PA Acute Stroke Study Group (1991) An open safety/ efficacy trial of rt-PA in acute thromboembolic stroke: final report. Stroke 22: 153Google Scholar
  117. Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR (1983) Platelets have more than one binding site for von Willebrand factor. J Clin Invest 72: 1–12PubMedGoogle Scholar
  118. Runge MS, Bode C, Matsueda GR, Haber E (1987) Antibodyenhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 84: 7659–7662PubMedGoogle Scholar
  119. Savage B, Ruggeri ZM (1991) Selective recognition of adhesive sites in surface-bound fibrinogen by GPIIb-IIIa on nonactivated platelets. J Biol Chem 266: 11227–11233PubMedGoogle Scholar
  120. Schwartz ML, Pizzo SV, Hill RL, McKee PA (1973) Human factor XIII from plasma and platelets. Molecular weight, subunit structures, proteolytic activation and cross-linking of fibrinogen and fibrin. J Biol Chem 248: 1395–1407Google Scholar
  121. Sjoholm I, Wiman B, Wallen P (1973) Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-aminohexanoic acid. Eur J Biochem 39: 471–479PubMedGoogle Scholar
  122. Skyhoj-Olsen T, Larsen B, Herring M, Skawer EB, Lassen NA (1983) Blood flow and vascular reactivity in collateral perfused brain tissue: evidence of an ischemic penumbra. Stroke 14: 332–341Google Scholar
  123. Smith RAG, Dupe RJ, English PD, Green J (1981) Fibrinolysis with acylenzymes: a new approach to thrombolytic therapy Nature 290: 505–508Google Scholar
  124. Smith RAG, Dupe FJ, English PD, Green J (1982) Acylenzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemost 47: 269–274PubMedGoogle Scholar
  125. Solis OJ, Roberson GR, Taveras JM, Neohr J, Pessin M (1977) Cerebral angiography in acute cerebral infarction. Revist Interam Radiol 2: 19–25Google Scholar
  126. Stump DC, Mann KG (1988) Mechanisms of thrombus formation and lysis. Ann Emerg Med 17: 1138–1147PubMedGoogle Scholar
  127. Sussman BJ, Fitch TSP (1958) Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 167: 1705–1709Google Scholar
  128. Taneda M, Shimada N, Tsuchiya T (1985) Transient neurological deficits due to embolic occlusion and immediate reopening of the cerebral arteries. Stroke 16: 522–524PubMedGoogle Scholar
  129. Theron J, Courtheoux P, Casaseo A et al. (1989) Local intraarterial fibrinolysis in the carotid territory. Am J Neuroradiol 10: 753–765PubMedGoogle Scholar
  130. Thorsen S, Phillips M (1984) Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma: evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 802: 111PubMedGoogle Scholar
  131. Verheijen JH, Chang GTG, Kluft C (1984) Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 51: 392PubMedGoogle Scholar
  132. Verstraete M, Collen D (1986) Thrombolytic therapy in the eighties. Blood 67: 1529–1541PubMedGoogle Scholar
  133. von Kummer R (1991) Intravenous tissue plasminogen activator in acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer-Verlag, Heidelberg, pp 161–167Google Scholar
  134. von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery. Stroke 23: 646–652Google Scholar
  135. White FW, Barlow GH, Mozen MM (1966) The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160–2169PubMedGoogle Scholar
  136. Wiman B, Chmielewska J, Ranby M (1984) Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 259: 3644PubMedGoogle Scholar
  137. Witt W, Baldus B, Bringmann P et al. (1992) The new plasminogen activators DSPAal and a2 from the vampire bat Desmodus rotundus. Fibrinolysis 6 (Suppl 2): 28 (Abstract)Google Scholar
  138. Yamaguchi T (1991) Intravenous rt-PA in acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer- Verlag, Heidelberg, pp 168–174Google Scholar
  139. Yamaguchi T, Minematsu K, Choki J-I, Ikeda M (1984) Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 48: 50–58PubMedGoogle Scholar
  140. Yamaguchi T, Hayaleawa T, Kileuchi H (1993) Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W (eds) Thrombolytic therapy in acute ischemic stroke II. Springer-Verlag, Heidelberg, pp 59–65Google Scholar
  141. Zeumer H (1985) Survey of progress: vascular recanalizing techniques in interventional neuroradiology. J Neurol 231: 287–294PubMedGoogle Scholar
  142. Zeumer H, Freitag HJ, Grzyka U, Neunzig HP (1989) Local intra-arterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology 31: 336–340PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1995

Authors and Affiliations

  • G. J. del Zoppo

There are no affiliations available

Personalised recommendations